Targeted Radiopharmaceuticals Summit EU 2026

Name: Targeted Radiopharmaceuticals Summit EU 2026
Start: 2026-12-08
End: 2026-12-10
Location: Renaissance London Heathrow Hotel

8 December 2026 – 10 December 2026

Renaissance London Heathrow Hotel, London, United Kingdom

The 8th Targeted Radiopharmaceuticals Summit Europe, organised by Hanson Wade, brings together scientific, clinical, manufacturing, regulatory and commercial leaders in targeted radiopharmaceuticals and radioligand therapy. The programme runs from a pre-conference seminar day through two main conference days, with parallel tracks on discovery and preclinical development, translational and clinical development, and supply chain and CMC, alongside plenary sessions with regulators, patients and investors.

70 sessions · 50 speakers

Organiser (1)

Hanson Wade

Media Partner (1)

Nuclio Media

Sponsors (10)

Trasis · Hiro · Beacon · Chelatec · Isotopia · Almac Group · Comecer · Perceptive · Starget Pharma · Navigo Proteins

Speakers (50)

Ajaaz Hussain Radiopharmaceutical Scientist, The Royal Marsden NHS
Rich Edwards Chief Technology Officer, Nuclide Therapeutics
Chaitanya Divgi Senior Expert - Strategic Therapeutic Innovation, Novartis
Friedmund Bachmann Vice President CMC & Project Lead, OncoOne
Graeme McRobbie Associate Director Formulation Science Radiopharmaceuticals, Bicycle Therapeutics plc
Guangzhou Han Chief Scientific Officer, RadAlliance Therapeutics Inc
Kevin Tabury Program Pipeline Manager - Head of Innovation & Translational Development Unit, Belgian Nuclear Research Center
Luke Brzozowski Executive Director, Theranostics, University Health Network
Martin Steegmaier Chief Scientific Officer, Molecular Partners
Michael Method Chief Medical Officer, Bicycle Therapeutics
Mohamad Haqiqian PET Radiopharmacy Production & QC Analyst, Radiation Safety Supervisor, Curium Pharma
Waisi Eng Chief Technology Officer, Norroy North America Inc.
Zahra Trippe Patient Engagement Lead Oncology, Bayer
Vicki Jardine Vice President - Global Clinical Development, Ratio Therapeutics
Ana Filipa Fonseca Director, Global RLT Strategy and Early Portfolio, Novartis AG
Andreas Furer Senior Regulatory Manager, Swiss Medic
Anil Lalwani Director - Regulatory Chemistry, Manufacturing, Controls & MedTech, Telix Pharmaceuticals
Cara Ferreira Chief Executive Officer, Lumina Pharmaceuticals
Chris Pak President & Chief Executive Officer, Molecular Targeting Technologies
David Gauden Chief Executive Officer, Blue Earth Therapeutics Ltd.
Dirk Pleimes Group Chief Executive Officer & Chief Marketing Officer, PentixaPharm GmbH
Frederic Desdouits Chief Executive Officer, OranoMed
Fredrik Frejd Chief Scientific Officer, Affibody AB
Gary Inwards Sr Pharmaceutical Assessor, MHRA
Guido Würth Head of Corporate Development & Radiopharma Medical & Health; Sales; Operations, Affibody AB
Haihong Jin Chief Scientific Officer, Vitsgen Therapeutics, Inc.
Ilya Folitar Senior Global Program Safety Team Lead and Radiopharmaceutical Safety Lead, Novartis
Jitka Riedl Associate Principal Scientist, Project Leader, Bicycle Therapeutics
Josie Gayton Chief Operating Officer, Precirix
Judson Kimmel Neuroendocrine Cancer & Theranostics Patient / Advocate, Man Up To Cancer
Julia Publicover Director, Translational Research & Innovation, University Health Network
Luigi Aloj Professor of Nuclear Medicine, University of Cambridge
Marc Robillard Chief Scientific Officer & Founder, Tagworks Pharmaceuticals BV
Mark Dornan Vice President of Pharmaceutical Development and External Manufacturing, Alpha-9 Oncology
Mark Fielding Director - Chemistry, Manufacturing, Controls, Regulatory Affairs & Radiopharmaceuticals, AstraZeneca
Ming Xu Vice President - Oncology & Product Team Lead, Bayer
Muhammet Tanc CEO, Nuclide Therapeutics
Oystein Soug Chief Executive Officer, Oncoinvent AS
Richard Pearson CEO, StandardX
Sandra Hennig Senior RA CMC Strategist, Bayer
Shefali Kakar Vice President, Global Head PK Sciences - Oncology, Novartis AG
Sigal Kalmanson Cusnir Chief Executive Officer, Starget Pharma
Tanja Aarvak Director, Program Management, Alpha Radioligand Therapy, ARTBIO
Tomohiko Yamane Director - Molecular Imaging Research, Kobe City Medical Center General Hospital
Dangshe Ma Sr. Dir, Regeneron
Daniel Squair S&E Manager, Jarlen Capital
Ian Poburenny Director, Rothschild & Co.
Kemp Dolliver Director of Research, Brookline Capital Markets
Kevin Madagan Partner, McGuireWoods
Kurt Pike Senior Director - External Innovation, JNJ

Targeted Radiopharmaceuticals Summit EU 2026

Organiser (1)

Media Partner (1)

Sponsors (10)

Speakers (50)

Agenda